Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Dna X (SONM) EBIAT (2018 - 2025)

Dna X filings provide 8 years of EBIAT readings, the most recent being $3.8 million for Q4 2025.

  • On a quarterly basis, EBIAT rose 117.65% to $3.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$8.0 million, a 76.36% increase, with the full-year FY2025 number at -$8.0 million, up 76.36% from a year prior.
  • EBIAT hit $3.8 million in Q4 2025 for Dna X, up from -$4.8 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $3.8 million in Q4 2025 to a low of -$21.6 million in Q4 2024.
  • Median EBIAT over the past 5 years was -$3.6 million (2022), compared with a mean of -$4.7 million.
  • Biggest five-year swings in EBIAT: skyrocketed 132.77% in 2023 and later plummeted 1497.49% in 2024.
  • Dna X's EBIAT stood at -$11.7 million in 2021, then skyrocketed by 91.11% to -$1.0 million in 2022, then fell by 29.85% to -$1.4 million in 2023, then plummeted by 1497.49% to -$21.6 million in 2024, then surged by 117.65% to $3.8 million in 2025.
  • The last three reported values for EBIAT were $3.8 million (Q4 2025), -$4.8 million (Q3 2025), and -$7.5 million (Q2 2025) per Business Quant data.